(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 July 2014 (17.07.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/108484 A3

(51) International Patent Classification:
C07K 16/28 (2006.01) *A61P 35/00* (2006.01)
C07K 16/32 (2006.01) *A61K 39/395* (2006.01)

(21) International Application Number:
PCT/EP2014/050344

(22) International Filing Date:
10 January 2014 (10.01.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
13151076.0 11 January 2013 (11.01.2013) EP

(71) Applicant *(for all designated States except US)*: **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacher Strasse 124, CH-4070 Basel (CH).

(71) Applicant *(for US only)*: **HOFFMANN-LA ROCHE INC.** [US/US]; 340 Kingsland Street, Nutley, New Jersey 07110 (US).

(72) Inventors: **BAUSS, Frieder**; Rottstrasse 11, 67141 Neuhofen (DE). **BOSSENMAIER, Birgit**; Horst-Wolfram-Geißler-Weg 10, 82229 Seefeld (DE). **FRIESS, Thomas**; St. Martin-Strasse 8a, 86911 Diessen-Dettenhofen (DE). **GERDES, Christian**; Sandfelsenstrasse 4, CH-8703 Erlenbach (CH). **HASMANN, Max**; Rudolf-Zenker-Strasse 10, 81377 Muenchen (DE). **THOMAS, Marlene**; Saalangerstraße 5, 82377 Penzberg (DE). **WEISSER, Martin**; Primel Strasse 1, 82377 Penzberg (DE).

(74) Agents: **JENNI, Wolfgang** et al.; Roche Diagnostics GmbH, Patent Department (LPP.....6164), P.O.Box 11 52, 82372 Penzberg (DE).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,

[Continued on next page]

(54) Title: COMBINATION THERAPY OF ANTI-HER3 AND ANTI-HER2 ANTIBODIES

(57) Abstract: The present invention relates to the combination therapy of anti-HER3 antibodies with certain anti-HER antibodies.

Fig. 7



WO 2014/108484 A3

MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:
4 September 2014